Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
4.460
-0.110 (-2.41%)
At close: Jul 13, 2026, 4:00 PM EDT
4.410
-0.050 (-1.12%)
After-hours: Jul 13, 2026, 4:10 PM EDT
Passage Bio Employees
Passage Bio had 24 employees as of December 31, 2025. The number of employees decreased by 36 or -60.00% compared to the previous year.
Employees
24
Change (1Y)
-36
Growth (1Y)
-60.00%
Revenue / Employee
n/a
Profits / Employee
-$1,569,833
Market Cap
14.31M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 24 | -36 | -60.00% |
| Dec 31, 2024 | 60 | 2 | 3.45% |
| Dec 31, 2023 | 58 | -27 | -31.76% |
| Dec 31, 2022 | 85 | -48 | -36.09% |
| Dec 31, 2021 | 133 | 59 | 79.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lunai Bioworks | 29 |
| Citius Pharmaceuticals | 23 |
| Jasper Therapeutics | 22 |
| CalciMedica | 16 |
| Cocrystal Pharma | 10 |
| Lexaria Bioscience | 7 |
| Tempest Therapeutics | 5 |
| GT Biopharma | 1 |
PASG News
- 19 days ago - Passage Bio trading resumes - TheFly
- 19 days ago - Passage Bio Transcript: M&A announcement - Transcripts
- 19 days ago - Passage Bio Press release: M&A announcement - Filings
- 19 days ago - Passage Bio, Remix Therapeutics to combine in all-stock transaction - TheFly
- 19 days ago - Passage Bio trading halted, news pending - TheFly
- 19 days ago - Passage Bio and Remix Therapeutics Announce Merger Agreement - GlobeNewsWire
- 4 weeks ago - Guggenheim downgrades Passage Bio to Neutral, terminates coverage - TheFly
- 4 weeks ago - Passage Bio downgraded to Neutral from Buy at Guggenheim - TheFly